1. The deep connection between pneumonia pathology and hypoxia dilemma

Pneumonia is an acute inflammation caused by pathogens invading the lungs, and its core pathological feature is alveolar ventilation dysfunction. When the alveoli are covered with inflammatory exudates, oxygen cannot effectively diffuse into the blood, and the blood oxygen saturation (SpO₂) will drop significantly. Clinical studies have shown that the arterial oxygen partial pressure (PaO₂) of patients with severe pneumonia is often lower than 60mmHg. At this time, the organs of the whole body are in a state of hypoxia, and the functions of important organs such as the brain and heart will be rapidly damaged.

The core value of the RESPIREASY oxygen concentrator lies in rebuilding the oxygen delivery channel. By separating oxygen from the air through molecular sieve technology, the oxygen concentrator can increase the oxygen concentration to more than 90% (medical standard), directly improving hypoxemia. For pneumonia patients with blood oxygen saturation below 93%, timely oxygen therapy can avoid irreversible organ damage and reduce mortality.

DEDAKJ Home Oxygen Therapy Oxygen Concentrator

Travel Portable Oxygen Therapy Concentrator

10-60L Fixed Medical Oxygen Concentrator

2. Technical evolution of RESPIREASY oxygen generator and adaptation to treatment scenarios

1. Analysis of core technologies

- Molecular sieve oxygen production: Through pressure swing adsorption (PSA) technology, high-purity oxygen is produced by utilizing the characteristics of zeolite molecular sieves that preferentially adsorb nitrogen. This is currently the only medical oxygen production technology that meets international standards, with a stability of more than 10,000 hours.

- Compressor performance: Oil-free pure copper compressors are key, and their continuous operation capacity directly affects the life of the oxygen generator. For example, the compressor used in the RESPIREASY KPC oxygen generator can work stably for 10,000 hours, and the gas volume exceeds the market theoretical value by 40%.

- Intelligent monitoring system: High-end models are equipped with oxygen concentration sensors and pressure monitoring modules to provide real-time feedback on the status of the equipment to ensure that the output oxygen concentration is stable at 95%±3%.

2. Grading application of treatment scenarios

- Mild pneumonia: Use 3L/min nasal cannula oxygen inhalation to maintain SpO₂≥94%. For example, patients with common bacterial pneumonia can relieve symptoms through home oxygen generators.
- Severe pneumonia: It is necessary to upgrade to a 5L or higher model and cooperate with high-flow humidified oxygen therapy (HFNC). Studies have shown that HFNC can increase the oxygenation index (OI) by 30%-50%, significantly improving respiratory distress.
- Critical pneumonia: When the oxygenation index is less than 150mmHg, non-invasive ventilation (NPPV) or invasive mechanical ventilation is required. At this time, the oxygen concentrator, as an oxygen source, needs to provide high-flow support of ≥8L/min.

III. Implementation strategy and risk prevention and control of RESPIREASY precision oxygen therapy

1. Dynamic evaluation system

- Blood oxygen monitoring: It is recommended to measure SpO₂ every 2 hours, and the target value is maintained at 94%-98%. If SpO₂ continues to be greater than 98%, it is necessary to be alert to the risk of oxygen poisoning and temporarily reduce the oxygen flow.
- Blood gas analysis: Regularly test the arterial oxygen partial pressure (PaO₂) and carbon dioxide partial pressure (PaCO₂) to adjust the oxygen therapy plan. For example, patients with COPD and pneumonia need to control the oxygen flow rate at 1-2L/min to avoid CO₂ retention.

2. Personalized treatment plan

- Pediatric pneumonia: Nasal cannula oxygen inhalation (0.5-1L/min) is the first choice for neonatal pneumonia, and premature infants need to strictly control the oxygen concentration to less than 30% to prevent retinopathy.

- Elderly pneumonia: For patients with heart failure, it is recommended to use 24-hour continuous low-flow oxygen inhalation (1-2L/min), while monitoring heart rate and blood pressure changes.

- Viral pneumonia: For influenza A combined with ARDS, high-flow oxygen therapy (40-60L/min) combined with prone ventilation is required to improve the ventilation-blood flow ratio.

3. Prevention of complications

- Oxygen poisoning: Avoid long-term inhalation of high-concentration oxygen > 60%. Intermittent oxygen inhalation can be set through the timing function (such as inhalation for 30 minutes, stop for 10 minutes).

- Airway dryness: A humidification bottle must be used. It is recommended to replace the sterile injection water daily to maintain the humidity of the inhaled gas at 40%-60%.
- Equipment infection: Wipe the body with chlorine-containing disinfectant every week, and replace the molecular sieve and filter membrane every 3 months to prevent bacterial growth.

IV. Selection criteria and usage specifications of RESPIREASY oxygen generator

1. Model selection guide

- Flow matching: 1-3L machine can be selected for daily health care, 5L or more models are required for COPD and severe pneumonia, and 10L machine is recommended for ARDS patients.
- Core components: Double-tower pure lithium molecular sieve (canned volume>30%) and oil-free compressor (noise<40 decibels) are preferred, such as RESPIREASY  ,  KPA , KPS,  KPC   etc.
- Intelligent functions: Models with oxygen concentration alarm, power-off protection, and remote monitoring are more suitable for home use, such as Meike H508W, which supports mobile phone APP to adjust parameters.

2. Key points of RESPIREASY operation specifications

- Safe use: The equipment should be kept away from fire sources (distance>1 meter) and avoid use in confined spaces. In high altitude areas, plateau models (such as Devibis) should be selected to prevent the oxygen production efficiency from decreasing.
- Maintenance: Clean the air filter every 500 hours of operation, and have a professional engineer calibrate the oxygen concentration sensor every year to ensure that the accuracy error is less than 2%.
- Emergency preparation: It is recommended to have a spare oxygen cylinder (capacity ≥ 40L) to deal with power outages or equipment failures. The pressure of the oxygen cylinder must be maintained above 10MPa to avoid insufficient oxygen in emergencies.

V. RESPIREASY clinical practice and research evidence support

1. Sequential treatment plan

For severe pneumonia combined with respiratory failure, studies have shown that "invasive mechanical ventilation-high flow oxygen therapy" sequential treatment can significantly improve blood gas indicators. Compared with traditional invasive-noninvasive sequential treatment, this program increased the oxygenation index by 23% and reduced the Borg dyspnea score by 35%.

2. The value of home oxygen therapy

For patients with COPD and pneumonia who receive long-term home oxygen therapy (> 15 hours/day), the 5-year survival rate can be increased by 40% and the number of hospitalizations can be reduced by 50%. For patients recovering from stable pneumonia, night oxygen therapy (started when SpO₂＜90%) can effectively prevent sleep apnea syndrome.

3. Management of special populations

- Newborns: When pneumonia is combined with hypoxemia, it is recommended to use a warm and humidified high-flow nasal cannula (2-4L/min) to avoid nasal damage caused by traditional masks.

- Elderly people: For patients with coronary heart disease, oxygen therapy can reduce myocardial oxygen consumption and reduce the frequency of angina attacks. Studies have shown that continuous low-flow oxygen inhalation reduces the incidence of cardiovascular events in elderly pneumonia patients by 28%.

VI. RESPIREASY future development trends and health management

1. Technology innovation direction

- Intelligent oxygen generation system: Combined with AI algorithms, it automatically adjusts the oxygen flow rate by real-time monitoring of SpO₂ and respiratory rate.

- Portable design: The new generation of portable oxygen generators (such as RESPIREASY KPA KPS) weighs only 1.8kg, has a battery life of 8 hours, and supports mobile oxygen therapy during outdoor activities.

2. Health management recommendations

- Vaccination: Influenza vaccine + pneumococcal vaccine combined vaccination can reduce the incidence of pneumonia by 65% and reduce the need for oxygen concentrators.

- Respiratory rehabilitation: After pneumonia is cured, abdominal breathing training (3 times a day, 10 minutes each time) and aerobic exercise (such as Ba Duan Jin) can increase the recovery rate of lung function by 30%.

- Environmental control: Use air purifiers (CADR value > 300m³/h) and humidity regulators (50%-60%) to reduce the concentration of indoor allergens and pathogens.

Summary;

As the core auxiliary equipment for pneumonia treatment, the value of oxygen concentrators lies not only in correcting hypoxemia, but also in gaining a precious treatment window for patients. Through accurate assessment of the condition, scientific selection of equipment, and standardized operation procedures, oxygen concentrators can become an "oxygen barrier" to protect life. For patients with pneumonia, the rational use of oxygen concentrators is a key link in achieving the transition from "passive treatment" to "active rehabilitation", and this process requires the joint participation of doctors, patients and their families to build a comprehensive respiratory health management system.

 

About DEDAKJ- RESPIREASY

Top rated oxygen concentrators supplier